Get started
Author

Alessia Ferrari

Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C
2006 · Giada Sebastiani, Alessandro Vario, et al. · Journal of Hepatology · 263
PDF
Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse
2005 · Martina Gerotto, Francesca Dal Pero, et al. · Journal of Hepatology · 49
PDF
Scalp Cooling in Daily Clinical Practice for Breast Cancer Patients Undergoing Curative Chemotherapy: A Multicenter Interventional Study
2019 · Emilia Gianotti, Giorgia Razzini, et al. · Asia-Pacific Journal of Oncology Nursing · 26
PDF
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial
2024 · Francesco Schettini, Michela Palleschi, et al. · The Oncologist · 16
PDF
High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders
2001 · Stefano Realdon, Patrizia Pontisso, et al. · Journal of Hepatology · 16
Pkr Gene Expression and Response to Pegylated Interferon plus Ribavirin Therapy in Chronic Hepatitis C
2004 · Martina Gerotto, Francesca Dal Pero, et al. · Antiviral Therapy · 10
PDF
Metabolic cofactors play an important role in fibrosis progression in initially mild chronic hepatitis C
2002 · Alfredo Alberti, Alessandro Vario, et al. · Journal of Hepatology · 2
Integrating supervised physical activity into breast cancer survivorship care.
2026 · Katia Cagossi, Giorgia Razzini, et al. · Journal of Clinical Oncology
Well-being Pathway (We-Path): An Italian integrative oncology community-based program for cancer survivors.
2025 · Giorgia Razzini, Laura Bernaroli, et al. · Journal of Clinical Oncology
PDF
Abstract PO3-14-06: Immunologic features and association with prognosis in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
2024 · Francesco Schettini, Michela Palleschi, et al. · Cancer Research
Response to Referee #2
2019 · Alessia Ferrari
PDF
Response to Referee II
2018 · Alessia Ferrari
Metronomic cyclophosphamide and capecitabine combined with lapatinib in heavily pretreated metastatic breast cancer (MBC) HER2-positive patients: 2-year update.
2013 · Katia Cagossi, Giorgia Razzini, et al. · Journal of Clinical Oncology
Metronomic cyclophosphamide and capecitabine combined with lapatinib in heavily pretreated metastatic breast cancer (MBC) HER2-positive patients.
2012 · Katia Cagossi, Maria Grazia Lazzaretti, et al. · Journal of Clinical Oncology
Nuovi sviluppi nel trattamento del carcinoma renale metastatico.
2008 · Roberto Sabbatini, Alessia Ferrari, et al. · Tumori
Carcinomi Mammari Her2 Positivi: Casistica Di Modena
2006 · S. Giovannelli, V. Guarneri, et al. · IRIS UNIMORE (University of Modena and Reggio Emilia)
Vitamin E does not reduce ribavirin associated anaemia during combination therapy for hepatitis C
2002 · Silvia Boccato, Alessia Ferrari, et al. · Journal of Hepatology
Different modulation of PKR gene expression by HCV genotypes
2002 · Martina Gerotto, Francesca Dal Pero, et al. · Journal of Hepatology
Works count: 19
Citation count: 382
H-index: 6
I10-index: 6
Year
Topic
Type